39 results about "Retinal Photoreceptor Cells" patented technology

The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. The invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system, such as the retina. The present invention provide agents which are able to diffuse readily and therefore can promote repair for neurodegenerative disease of the eye, such as macular degeneration. The present invention further provides methods of treating macular degeneration, methods of inhibiting or reducing the rate of subretinal neovascularization and proliferation of neovascular tissue and methods of protecting retinal photoreceptor cell death.

Methods for ophthalmic lens design incorporating a visual acuity profile are disclosed. The methods include applying rules and functions to visual acuity profile data and an ophthalmic prescription to generate ophthalmic lens parameters for a subject. The visual acuity profile data includes a maximum visual acuity for the subject. The visual acuity profile data may also include a focus tolerance or tolerable blur. Tolerable blur may be measured by an ophthalmic professional or extrapolated. The visual acuity profile data may also include eye physical data such as pupil diameter and eye size, accommodation, retinal photoreceptor cell packing information and neural processing information. The visual acuity profile data may also include personal biographic and / or medical information for the subject.

The invention relates to a co-culture method of photosensory precursor cells and retinal tissue in vitro and aims to build a co-culture system for the photosensory precursor cells and denaturation retinal tissue of retina photoreceptor cells. The method comprises the following steps: a photosensory precursor cell layer of an embryonic eye source is prepared; a nerve cell layer of a denatured retina is prepared; the nerve cell layer of the denatured retina is placed on the photosensory precursor cell layer; an epithelial layer of retinochrome is prepared in the lower chamber of a plug-in type tissue culture dish; the co-culture system of the retinal tissue and cells is built in vitro, and the retinal tissue and cells are cultured in an incubator with 5% CO2 at the temperature of 37 DEG C. By adopting the method provided by the invention, the biological characteristics and cellular structure of host cells and transplanted cells, the synaptic contact of the transplanted cells and the host cells, and the chromatin conformation reconstruction of the transplanted cells and the host cells can be observed and detected directly in vitro, and the traces of survival, proliferation, differentiation and functional reconstruction of photosensory precursor cells of a transplanted embryonic eye source can be tracked.

The invention discloses a traditional Chinese medicine composition for treating juvenile myopia. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of salvia miltiorrhiza, 6-10 parts of smilax riparia, 6-14 parts of silene conoidea, 11-15 parts of herba pyrolae, 2-4 parts of rhizoma sparganii, 9-13 parts of artemisia anomala, 5-9 parts of astragalus, 3-5 parts of acacia catechu, 6-10 parts of semen cuscutae, 10-20 parts of plantain herb, 2-4 parts of shamrock, 1-3 parts of passion flowers, 4-8 parts of gynostemma pentaphylla and 5-10 parts of paris polyphylla. The traditional Chinese medicine composition disclosed by the invention has the effects of enriching qi and activating blood, tonifying deficiency and tonifying the kidney, nourishing the liver to improve visual acuity and inducing diuresis and reducing edema, so that the liver is full of yin blood, the hepatic and renal functions are normal, the retina photoreceptor cell function is enhanced, the ocular tissues are solid, and neurotrophic factors in the retina and cell layers are increased. Moreover, sufficient nutrition of the eye system is obtained, the ocular material and functional metabolism are normal, the self-healing ability and resistance of the organism are enhanced, the juvenile myopia is fundamentally treated, and the traditional Chinese medicine composition can treat both symptoms and root causes and does not have any toxic and / or side effect.

The invention relates to a method for inducing the differentiation of human amniotic epithelial cells into retinal photoreceptor cells and its application in treating retinal degenerative diseases. The invention provides a method for inducing the differentiation of human amniotic epithelial cells into retinal photoreceptor cells, culturing human amniotic epithelial cells under suitable conditions, adding an inducing composition to induce the differentiation of human amniotic epithelial cells into retinal photoreceptor cells, and inducing the cells produced High expression of typical genes of retinal photoreceptor cells such as Chx10, Rx, Crx, NRL. After the induced differentiation cells were collected and injected into the subretinal space, the electrophysiological signals of the eye were significantly enhanced, the fundus structure was significantly improved, and the retinal thickness was significantly increased through ERG and OCT detection, which showed that it could treat and / or improve the progress of retinal degenerative diseases. The clinical application of ophthalmic diseases will have broad prospects.

The invention discloses an application of a traditional Chinese medicine composition in alleviating visual fatigue and preventing, delaying and treating myopia and its complications. Part Huaijiao, 3-15 parts by weight Phellodendron Phellodendri, 5-15 parts by weight Shayuanzi and 1-3 parts by weight pearl powder, preferably also include 1-3 parts by weight amber powder and 6-15 parts by weight Chuan Fritillaria. Among them, Dangshen and Shayuanzi benefit yang, invigorate the spleen and improve eyesight, and increase the function of retinal photoreceptor cells are the monarch drugs; Huaijiao and Cortex Phellodendri can clear the liver and improve eyesight, bitter cold and harden yin, and clear the deficiency heat of the retinal pigment cell layer are the ministerial drugs; pearl powder calms the nerves and strengthens the body , to strengthen the tenacity of scleral tissue as an adjuvant drug, the above-mentioned medicinal materials are formulated with "Yin Yang Jian Yin" as the treatment principle, the taste of the medicine is simple, the property of the medicine is mild, and they cooperate with each other and act synergistically. Inhibit the deformation of sclera, strengthen the function of retinal pigment cells, so as to prevent, delay and control the development of myopia.

The invention relates to the construction and application of an animal model of chronic drug toxicity retinal photoreceptor cell damage, and aims to solve the technical problem that there is no relevant animal model in the prior art. The present invention mainly constructs an animal model of chronic drug toxicity retinal photoreceptor cell damage by injecting methyl methanesulfonate into the tail vein of mice at a dosage of 40-60 / (kg·body weight). The invention establishes an animal model of chronic drug retinal photoreceptor cell injury for the first time, and can provide a reliable and stable animal model for studying the molecular regulation effect of epigenetic modification on the transdifferentiation and regeneration of endogenous stem cells in the process of retinal injury, pathogenesis and intervention therapy It also lays a material and technical foundation for people to more effectively understand the mechanism and development of retinal drug toxicity diseases and to study intervention and treatment measures.

The invention relates to the technical field of stem cells, and especially relates to a method and kit for identifying retinal progenitor cells capable of treating retinal degenerative change. The method comprises the following steps: culturing retinal progenitor cells to the logarithmic phase, and carrying out flow cytometry identification, wherein the retinal progenitor cells that meet the identification standards are capable of treating retinal degenerative change. The retinal progenitor cells identified by the provided method can maintain a good proliferation performance and stem cell characteristics and have a good curative effect when being applied to the treatment on retinal degenerative change. The experiment results show that after the retinal progenitor cells identified by the provided method are injected into the vitreous body cavities of RCS mice, the retinal outer nuclear layer cells are protected; the multifocal visual electrophysiology examination results show that the change of potential transmitted by retinal photoreceptor cells of the cell injection group is more prominent than the group, which is only injected with a HBSS buffer solution. The water maze experiment results also show that after injection, the visual performance of mice is improved.